APG-157 for advanced head and neck cancer
Treatments studied
Part of Cancer, Mouth & dental clinical trials.
This trial tests an experimental drug called APG-157 in people with advanced head and neck cancers of the mouth or throat. It is designed for those who are not eligible for certain standard treatments or who can have surgery or chemoradiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- Your cancer must be in the oral cavity (mouth) or oropharynx (back of the throat) and has not been treated before
- Your cancer must be stage III or IVA (advanced but not spread to distant parts of the body)
- You must be able to have surgery to remove the cancer (Cohort A) OR you must be able to receive chemotherapy and radiation (Cohort B)
- You must be medically unable to receive the immunotherapy drug pembrolizumab (if you are in Cohort A)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy drugs and an HPV vaccine alongside chemotherapy and radiation for throat cancers caused by HPV. The goal is to see if this approach works as well as standard treatment while using less radiation, potentially reducing side effects.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This is an early-stage trial testing a new drug called CRPA1A2 that trains your immune cells to fight certain cancers. The drug targets tumors that have specific genetic markers (MAGE-A1 and HLA-A*02:01). You may qualify if you have advanced cancer that hasn't responded to standard treatments.
This Phase 2 trial studies whether APG-157 can safely improve abnormal cells in the mouth (dysplasia) or early cancer-like changes (carcinoma in situ). You may be eligible if you have a visible, biopsy-proven lesion and can take oral medication while meeting blood and health requirements.
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.